Table 3 treatment, delay to start of treatment and outcome of published cases
age | sex | dosis | delay | treatment | outcome | author |
|---|---|---|---|---|---|---|
41 | f | 200 mg/m2 | 4 hours | HD | alive, n.s. | Brivet et al. |
36 | m | 480 mg/m2 | 6 days | HD | alive, CRF, hearing loss | Schiller et al. |
62 | m | 240 mg/m2 | 3 days | STS, HD | alive, n.a. | Delanian et al. |
68 | f | 280 mg/m2 | 12 days | PPH, HD | alive, CRF, hearing loss | Chu et al. |
54 | f | 205 mg/m2 | 6 days | HD | alive, n.a. | Lagrange et al. |
59 | m | 300 mg/m2 | 3 days | PPH | alive, n.s. | Jung et al. |
38 | f | total 640 mg | 4 days | NAC | dead | Sheik-Hamad et al. |
14 | f | 360 mg/m2 | 70 hours | STS | alive, hearing loss | Erdlenbruch et al. |
48 | m | 400 mg/m2 | no delay | PPH, HD | alive, n.s. | Choi et al. |
63 | m | total 750 mg | no delay | HD, NAC, PPH | dead | Charlier et al. |